Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study.

Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N.

J Clin Oncol. 2002 Jan 1;20(1):42-51.

PMID:
11773152
2.

Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study.

Bahl M, Ennis M, Tannock IF, Hux JE, Pritchard KI, Koo J, Goodwin PJ.

Breast Cancer Res Treat. 2005 Nov;94(2):135-44.

PMID:
16261412
3.

Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes.

Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Hartwick W, Hoffma B, Hood N.

Breast Cancer Res Treat. 2002 Jul;74(1):65-76.

PMID:
12150454
4.

Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women.

Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD.

J Natl Cancer Inst. 2009 Jan 7;101(1):48-60. doi: 10.1093/jnci/djn415.

5.

Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations.

Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Taylor SK, Hood N.

J Clin Oncol. 2012 Jan 10;30(2):164-71. doi: 10.1200/JCO.2011.36.2723.

PMID:
22162568
6.

Fasting glucose is a risk factor for breast cancer: a prospective study.

Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Sch√ľnemann HJ, Ram M, Freudenheim JL, Sieri S, Trevisan M, Berrino F.

Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1361-8.

7.

Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer.

Tibau A, Ennis M, Goodwin PJ.

Breast Cancer Res Treat. 2013 Oct;141(3):485-93. doi: 10.1007/s10549-013-2694-8.

PMID:
24072269
8.

Fasting blood glucose and long-term prognosis of non-metastatic breast cancer: a cohort study.

Contiero P, Berrino F, Tagliabue G, Mastroianni A, Di Mauro MG, Fabiano S, Annulli M, Muti P.

Breast Cancer Res Treat. 2013 Apr;138(3):951-9. doi: 10.1007/s10549-013-2519-9.

9.

Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer.

Mulligan AM, O'Malley FP, Ennis M, Fantus IG, Goodwin PJ.

Breast Cancer Res Treat. 2007 Nov;106(1):39-47.

PMID:
17221153
10.

Is leptin a mediator of adverse prognostic effects of obesity in breast cancer?

Goodwin PJ, Ennis M, Fantus IG, Pritchard KI, Trudeau ME, Koo J, Hood N.

J Clin Oncol. 2005 Sep 1;23(25):6037-42.

PMID:
16135472
11.

Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project.

Kwan ML, Chen WY, Kroenke CH, Weltzien EK, Beasley JM, Nechuta SJ, Poole EM, Lu W, Holmes MD, Quesenberry CP Jr, Pierce JP, Shu XO, Caan BJ.

Breast Cancer Res Treat. 2012 Apr;132(2):729-39. doi: 10.1007/s10549-011-1914-3.

12.

Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.

Krajcik RA, Borofsky ND, Massardo S, Orentreich N.

Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1566-73.

13.

High fasting blood glucose and obesity significantly and independently increase risk of breast cancer death in hormone receptor-positive disease.

Minicozzi P, Berrino F, Sebastiani F, Falcini F, Vattiato R, Cioccoloni F, Calagreti G, Fusco M, Vitale MF, Tumino R, Sigona A, Budroni M, Cesaraccio R, Candela G, Scuderi T, Zarcone M, Campisi I, Sant M.

Eur J Cancer. 2013 Dec;49(18):3881-8. doi: 10.1016/j.ejca.2013.08.004.

PMID:
24011933
14.

Body weight correlates with mortality in early-stage breast cancer.

Enger SM, Greif JM, Polikoff J, Press M.

Arch Surg. 2004 Sep;139(9):954-58; discussion 958-60.

PMID:
15381612
15.

Associations of insulin resistance and adiponectin with mortality in women with breast cancer.

Duggan C, Irwin ML, Xiao L, Henderson KD, Smith AW, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard-Barbash R, McTiernan A.

J Clin Oncol. 2011 Jan 1;29(1):32-9. doi: 10.1200/JCO.2009.26.4473.

16.

Insulin, macronutrient intake, and physical activity: are potential indicators of insulin resistance associated with mortality from breast cancer?

Borugian MJ, Sheps SB, Kim-Sing C, Van Patten C, Potter JD, Dunn B, Gallagher RP, Hislop TG.

Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1163-72.

17.

Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study.

Allin KH, Nordestgaard BG, Flyger H, Bojesen SE.

Breast Cancer Res. 2011 Jun 3;13(3):R55. doi: 10.1186/bcr2891.

18.

Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.

Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O'Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, Pollak MN.

J Clin Oncol. 2011 Oct 10;29(29):3869-76. doi: 10.1200/JCO.2010.33.7006.

PMID:
21911723
19.

Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population.

Kamineni A, Anderson ML, White E, Taplin SH, Porter P, Ballard-Barbash R, Malone K, Buist DS.

Cancer Causes Control. 2013 Feb;24(2):305-12. doi: 10.1007/s10552-012-0115-7.

20.

Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study.

Irwin ML, Duggan C, Wang CY, Smith AW, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard-Barbash R.

J Clin Oncol. 2011 Jan 1;29(1):47-53. doi: 10.1200/JCO.2010.28.4752.

Items per page

Supplemental Content

Support Center